N/A N=114 DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Chronic Kidney Disease
Primary: Percentage of Contrast Media Volume Saved — 40.1 % CMV savings per procedure
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=746 Oral Hygiene and Maternity Outcomes Multicenter Study (OHMOM)
Gingivitis · Pregnancy
Primary: Change From Baseline in Löe-Silness Gingivitis Index — 0.141; 0.154 score on a scale
Phase 2 N=12 Phase I/II Study of SRP-4053 in DMD Patients
Duchenne Muscular Dystrophy
Primary: Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Discontinuation — 4; 5; 5; 3 Participants
N/A N=132 SNaP Wound Care System Versus Traditional NPWT Device for Treatment of Chronic Wounds
Ulcers · Wounds
Primary: Percent Change in Wound Area — -85.7; -94 percentage of baseline wound area
Phase 2 N=55 Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer
Carcinoma, Non Small Cell Lung
Primary: Recommended Phase 2 Dose (RP2D) - Phase 1 — 45 mg
N/A N=189 Evaluation of the SEM Scanner 200 for the Detection of Early Pressure Ulcers: A Multi-Site Longitudinal Study
Pressure Ulcers
Primary: The Sensitivity of the SEM Scanner Device (70% or Above) for Detecting Early Pressure Ulcers Before Routine Skin Assessments — 87.5 percentage of true positives
N/A N=795 Association of Hepatitis C Virus With Breast Cancer
Breast Cancer · Hepatitis C
Primary: Prevalence of HCV Seropositivity in Breast Cancer Patients. — 88; 15; 317; 130 Participants — p=0.0027
Phase 2 N=10 A Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty
Subjects Requesting and Requiring an Open Rhinoplasty
Primary: Edema Severity — 1.25; 1.5; 1.25; 1 units on a scale
Phase 2 N=28 Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD
Posttraumatic Stress Disorder
Primary: Change in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score From Baseline to One Month Post 2nd Experimental Session — -26.3; -24.4; -11.5…
Phase 3 N=381 A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
Arthritis, Psoriatic
Primary: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 — 22.2; 52.0; 59.4 percentage of participants — p=< 0.001
Phase 3 N=453 Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study
Childhood Absence Epilepsy · Petit Mal Epilepsy · Epilepsy
Primary: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy — 81; 43; 85 Participants — p=<0.001
Phase 2 N=9 M7824 in People With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis · Respiratory Papillomatosis · Laryngeal Papilloma, Recurrent
Primary: Proportion of Participants With a Complete Response — 0; 0 proportion of participants
Phase 2 N=149 Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)
Psoriatic Arthritis
Primary: Percentage of Participants Who Achieved American College of Rheumatology (ACR) 20 Response at Week 24 — 18.4; 58.0 percentage of participants — p=<0.001
Phase 4 N=131 Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
Age-Related Macular Degeneration · Retinal Vein Occlusion · Diabetic Macular Edema
Primary: Change From Baseline in Mean Endothelial Cell Density — -35.86 cells/millimeter squared
Phase 3 N=58 Studying the Effects of Administration of Polyunsaturated Fatty Acids (PUFAS) of Omega-3 Series in Nicotine Dependence
Tobacco Dependence · Nicotine Dependence
Primary: Fageström Test for Nicotine Dependence Score at Baseline and After 90 Days of the Treatment — 6.53; 6.56; 5.96; 5.22 units on a scale